Pharma sours on the U.K., plus biotech M&A’s quiet roll

Will pharma companies invest in the U.K. again?

September 19, 2025 Check out STAT+

Sponsored By

Are pharmaceutical companies pulling their money out of the United Kingdom because of Trump? How is biotech M&A pacing this year? And what will vaccine advisors discuss at their closely watched meeting this week? STAT's European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money elsewhere. We also discuss the Advisory Committee on Immunization Practices, or ACIP, meeting and biotech M&A, including Roche's $3.5 billion acquisition of 89bio and its MASH drug, announced this week. LISTEN NOW Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode Visit the archive to see past episodes

---

---

Enjoying The Readout LOUD? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser